. Author manuscript; available in PMC: 2014 Jul 9.

Published in final edited form as: Res Social Adm Pharm. 2010 Jun;6(2):90–99. doi: 10.1016/j.sapharm.2010.02.004

Table 2.

Results for Part D Policy Effect Across Levels of Pre-Part D Out-of-Pocket Drug Spending (DDD Regression Models)

	Highest vs. Moderate	Highest vs. Lowest	Moderate vs. Lowest

Total Spending	225.2 (−36.4 – 712.6)	152.7^* (20.0 – 300.4)	−72.5 (−568.6 – 141.5)

Patient Out-of-Pocket Drug	−234.2^*	−227.8^*	6.4
Spending	(−286.3 – −180.1)	(−286.9 – −172.5)	(−15.7 – 28.2)

% Spending Out-of-Pocket	−6.2^*	−20.2^*	−13.9^*
% Spending Out-of-Pocket	(−8.7 – −3.9)	(−24.2 – −16.5)	(−17.9 – −10.1)

Pill-days	16.8	68.3^*	51.5^*
Pill-days	(−30.5 – 64.4)	(17.6 – 114.8)	(15.5 – 84.6)

p < 0.05.

Note: The numbers are coefficients (95% Bias Corrected Confidence Interval). The coefficients represent the difference in the change in the level of a dependent variable in the post-period relative to the pre-period for Part D eligibles relative to the control group between each level of pre-Part D out-of-pocket drug spending. The value of −234.2 in column two for Patient Out-of-Pocket Drug Spending suggests that the policy effect of Part D resulted in a significantly greater reduction in out-of-pocket drug spending of $234 after availability of Part D for eligible seniors with the highest level of pre-part D spending compared to eligible seniors with a moderate level of pre-Part D spending relative to the control group.